OBPgp279 is an endolysin that hydrolyzes peptidoglycan, a major constituent in bacterial membrane. OBPgp279 is found in Pseudomonas fluorescens phage OBP, which belongs in the Myoviridae family of bacteriophages. Because of its role in hydrolyzing the peptidoglycan layer, OBPgp279 is a key enzyme in the lytic cycle of the OBP bacteriophage; it allows the bacteriophage to lyse its host internally to escape. Unlike other endolysins, OBPgp279 does not rely on holins to perforate the inner bacterial membrane in order to reach the peptidoglycan layer. Although OBPgp279 is not a well-studied enzyme, it has garnered interest as a potential antibacterial protein due to its activity against multidrug-resistant gram-negative bacteria.
The mechanism of OBPgp279 is predicted to be analogous to glycoside hydrolase family 19 due to the presence of a conserved sequence motif in the catalytic domain of the enzyme. Glycoside hydrolase family 19 is a group of endo-acting enzymes that hydrolyzes the glycosidic bonds of β-1,4-linked N-Acetylglucosamine typically within chitin; however, some enzymes in this family also demonstrate lysozyme activity. Since bacterial cell walls do not contain chitin, OBPgp279 hydrolyzes β-1,4-linked GlcNAc in peptidoglycan. The hydrolysis of β-1,4-linked GlcNAc is catalyzed by two glutamate residues in the active side, one acting as a general acid, and another acting as a general base. There is limited detail on the catalytic mechanism of OBPgp279. However, because OBPgp279 is analogous to family 19, it is possible to infer the structure of OBPgp279 binding to peptidoglycan from the substrate binding of glycoside hydrolase family 19. The figure on the right shows an example of a glycoside hydrolase family 19 binding to chitin. OBPgp279 most likely has a similar active site, but it binds to peptidoglycan instead of chitin. Due to the activity of OBPgp279 on β-1,4-linked GlcNAc, it is likely that OBPgp279 is a N-acetylmuramidase endolysin which hydrolyzes the sugar backbone component of the peptidoglycan on the reducing side of GlcNAc.
The catalytic domain of the enzyme resides on the C-terminal region of the enzyme. OBPgp279 is also predicted to contain peptidoglycan binding domains; since OBPgp279 contains two peptidoglycan binding domain motifs in its N-terminal region, it likely contains two peptidoglycan binding domains as shown in the schematic drawing below.
Application
OBPgp279 has gained attention as a potential antibiotic because of the increasing prevalence of multidrug resistantgram-negative bacteria. Typically, most endolysins rely on holin to reach the peptidoglycan layer of gram-negative bacteria. This limits their efficacy as standalone antibiotics; without holins or any membrane permeabilizers, they have low membrane penetration. In contrast, OBPgp279 is capable of penetrating the bacterial outer membrane to reach the peptidoglycan layer without needing holins or any membrane permeabilizers. In addition, unlike most endolysins, OBPgp279 demonstrates high efficacy against a variety of bacteria instead of being species-specific. Compared to small molecule antibiotics, OBPgp279 also has the advantages of a low chance of bacterial resistance, specificity towards pathogen-causing bacteria, and efficacy on mucosal surfaces. In 2013, KU Leuven professor Rob Lavigne modified OBPgp279 by adding a polycationic nonapeptide to its C-terminus, thereby improving its efficacy as an antibiotic. The addition of the polycationic nonapeptide improved OBPgp279’s log reduction against various gram-negative and gram-positive bacteria by as much as three logs. This improvement is likely because of increased outer membrane penetration, in turn caused by favorable electrostatic interaction between the cationic nonapeptide and the negatively charged bacterial membrane. The engineered OBPgp279, along with the engineering technology platform, is currently owned by Boehringer Ingelheim Vetmedica. The major drawback of working with OBPgp279 and other endolysins is their immunogenicity. Although studies have shown that antibodies do not affect the efficacy of endolysins in animal models, immunogenicity will need to be monitored if OBPgp279 is pursued for medical use.
